Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Second tranche
View:
Post by riverrrow on Jul 10, 2024 11:45am

Second tranche

If you want to get a sense of second tranche financing check out how things are working out for VPT and its tranche financing.
Comment by Alamir1111 on Jul 10, 2024 12:08pm
Kind of read their bullboard post there is talk about big investors joining in.?is this a stock house playbook for pumpers to post?
Comment by Kayz88 on Jul 10, 2024 1:20pm
Second tranche for $180,000
Comment by Alamir1111 on Jul 10, 2024 1:37pm
April pp The Company plans to use the proceeds of the financing to further the Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study currently underway, preclinical research and development of Rutherrin®, working capital and general corporate purposes. Jul pp The Company plans to use the proceeds of the financing to further the Phase II Non-Muscle Invasive Bladder ...more  
Comment by Alamir1111 on Jul 10, 2024 1:57pm
Based on the latest research detailing RuvidarTM's success in the destruction of various viruses, the Company has gained consensus from the National Microbiology Laboratory to direct its research away from the Covid-19 virus vaccine to develop this technology for an avian influenza vaccine."  addition, when the human coronavirus was treated with RuvidarTM, the spike protein remained ...more  
Comment by plantrader on Jul 10, 2024 2:06pm
For TLT? If that's all the additional $ they can raise, then so much for the other indications making progress, right? Brain cancer, lung cancer, etc, etc. Is that right? If that's how it goes, then is the picture being painted that almost everything (all forms of progress) are hinging on NMIBC getting FDA BTD? Unless a hail mary buyout or big investor steps in. But that's always the ...more  
Comment by Kayz88 on Jul 10, 2024 3:17pm
No. For VPT, they raised $180k in their second tranche
Comment by plantrader on Jul 10, 2024 3:23pm
Ok good, thanks for clarifying. I was hoping you'd say that :-)
Comment by Legit62 on Jul 10, 2024 6:29pm
Where did you find this info??
Comment by Legit62 on Jul 10, 2024 6:29pm
Is PP closed??
Comment by Lesalpes29 on Jul 10, 2024 9:32pm
Not closed yet. First tranche done. Probably more tranches to come.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250